MetaVia (MTVA) Emerging Growth Conference 93 summary

Key clinical updates

• Presented new safety data for DA-1726 at EASL, showing no heart rate abnormalities in phase I trials.

• DA-1726 demonstrated a dose-dependent, textbook-like PK profile; phase I part three is ongoing with higher dose titration, aiming for 16-week data by year-end.

• Vanoglipol met primary endpoints in phase IIa for MASH; focus is now on its combination potential with other agents.

Combination therapy insights

• Vanoglipol combined with resmetirom in mice led to 23.6% weight loss and 43.5% fat mass reduction, with increased food intake but improved energy expenditure.

• Combination therapy showed better NAS improvement and liver steatosis reduction than monotherapies.

• Vanoglipol plus metformin resulted in 16.3% weight loss and significant fat mass reduction, attributed to increased GLP-1 and Peptide YY.

• Metformin combo also improved fasting glucose levels compared to monotherapies.

• Ongoing exploration of vanoglipol combinations with other diabetes and MASH drugs, with plans to meet FDA for next phase II trial.

Financial and operational outlook

• Cash reserves are sufficient to fund ongoing phase I, part three clinical trials for DA-1726 through Q4.

• Progressing smoothly with DA-1726 titration and actively developing new strategies for vanoglipol.